Jasper Therapeutics(US:JSPR) Businesswireยท2025-11-07 19:06Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to contact them regarding a class action lawsuit due to allegations of misleading business operations [1][2]. Summary by Sections Allegations - The lawsuit claims that Jasper Therapeutics made false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of products like briquilimab [3]. - Potential for disruptive cost-reduction measures due to the aforementioned failures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Public statements made by defendants were materially false and misleading [3]. Class Action Participation - Investors may be eligible to participate in the class action against Jasper Therapeutics, with a deadline to file motions for lead plaintiff by November 18, 2025 [4]. - Investors do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].